Skip to main content

Advertisement

SpringerLink
Log in

Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease

  • Brief Report
  • Published:
Virchows Archiv Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672–2681

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rosai J, Dorfman RF (1969) Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol 87:63–70

    CAS  PubMed  Google Scholar 

  3. Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A, Vaglio A et al (2017) Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol 18:e113–e125

    Article  PubMed  Google Scholar 

  4. Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B, Cohen-Aubart F et al (2012) High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120:2700–2703

    Article  CAS  PubMed  Google Scholar 

  5. Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z et al (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6:154–165

    Article  CAS  PubMed  Google Scholar 

  6. Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, Lim KP et al (2014) Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124:3007–3015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S et al (2015) Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Oncotarget 6:19819–19825

    Article  PubMed  PubMed Central  Google Scholar 

  8. Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, Liu X (2015) Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet 24:2125–2137

    Article  CAS  PubMed  Google Scholar 

  9. Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovee JV, Patel B, Badalian-Very G et al (2015) MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 54:361–368

    Article  CAS  PubMed  Google Scholar 

  10. Middel P, Hemmerlein B, Fayyazi A, Kaboth U, Radzun HJ (1999) Sinus histiocytosis with massive lymphadenopathy: evidence for its relationship to macrophages and for a cytokine-related disorder. Histopathology 35:525–533

    Article  CAS  PubMed  Google Scholar 

  11. Venkataraman G, McClain KL, Pittaluga S, Rao VK, Jaffe ES (2010) Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease. Am J Surg Pathol 34:589–594

    Article  PubMed  PubMed Central  Google Scholar 

  12. Agarwal A, Pathak S, Gujral S (2006) Sinus histiocytosis with massive lymphadenopathy--a review of seven cases. Indian J Pathol Microbiol 49:509–515

    PubMed  Google Scholar 

  13. Krzemieniecki K, Pawlicki M, Marganska K, Parczewska J (1996) The Rosai-Dorfman syndrome in a 17-year-old woman with transformation into high-grade lymphoma. A rare disease presentation. Ann Oncol 7:977

    Article  CAS  PubMed  Google Scholar 

  14. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290

    Article  CAS  PubMed  Google Scholar 

  15. Zhao Y, Adjei AA (2014) The clinical development of MEK inhibitors. Nat Rev Clin Oncol 11:385–400

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work has been supported by Krebsliga beider Basel and Stiftung zur Krebsbekämpfung Zürich

Authorship

MSM, DJ, and AT designed the study, analyzed data, and wrote the paper. MB analyzed data.

Author information

Authors and Affiliations

  1. Institute of Pathology, University of Basel, Schönbeinstrasse 40, 4003, Basel, Switzerland

    Matthias S. Matter, Michel Bihl, Darius Juskevicius & Alexandar Tzankov

Authors
  1. Matthias S. Matter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Bihl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darius Juskevicius
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandar Tzankov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandar Tzankov.

Ethics declarations

The authors confirm to have complied with ethical standards.

Conflict of interest

The authors have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matter, M.S., Bihl, M., Juskevicius, D. et al. Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease. Virchows Arch 471, 545–547 (2017). https://doi.org/10.1007/s00428-017-2173-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-017-2173-4

Search

Navigation